Various mechanisms can lead to abnormal activation of mTOR in RCC, including PTEN functional deficiency, enhanced function of PI3K catalytic subunits, and LKB1 gene mutations.2, 50, 51, 52, 53, 54, 55. This evidence concerns the gene MTOR and renal cell carcinoma.